Summary
Thermo Fisher Scientific Inc. reported robust revenue growth of 18% and 19% for the three and six months ended July 2, 2022, respectively, reaching $10.97 billion and $22.79 billion. This growth was largely driven by the Laboratory Products and Biopharma Services segment, significantly boosted by the acquisition of PPD, Inc. and strong performance in other areas. Despite this top-line strength, reported operating income and margins declined year-over-year, primarily due to the impact of acquisitions, lower COVID-19 testing volumes, and strategic growth investments. While overall revenue growth was strong, a notable trend is the decrease in sales related to COVID-19 testing, which impacted the Life Sciences Solutions and Specialty Diagnostics segments. The company's adjusted earnings per share remained relatively stable, reflecting management's focus on core operational performance. Despite pressures on GAAP margins, Thermo Fisher demonstrated strong cash flow generation, with $3.73 billion in operating cash flow for the six-month period. The company's liquidity position remains solid, with ample access to credit facilities.
Financial Highlights
54 data points| Revenue | $10.97B |
| R&D Expenses | $365.00M |
| SG&A Expenses | $2.21B |
| Operating Expenses | $8.97B |
| Operating Income | $2.00B |
| Interest Expense | $148.00M |
| Net Income | $1.67B |
| EPS (Basic) | $4.25 |
| EPS (Diluted) | $4.22 |
| Shares Outstanding (Basic) | 392.00M |
| Shares Outstanding (Diluted) | 394.00M |
Key Highlights
- 1Total revenues increased by 18% to $10.97 billion for the three months ended July 2, 2022, and by 19% to $22.79 billion for the six months ended July 2, 2022, year-over-year.
- 2The Laboratory Products and Biopharma Services segment saw significant revenue growth, fueled by the acquisition of PPD, Inc. and strong performance in other areas of the segment.
- 3Despite revenue growth, GAAP operating income and margins decreased year-over-year, attributed to acquisition impacts, lower COVID-19 testing volumes, and strategic investments.
- 4Sales related to COVID-19 testing declined, impacting the Life Sciences Solutions and Specialty Diagnostics segments, though this was partially offset by growth in other product lines and services.
- 5The company generated $3.73 billion in net cash from operating activities for the six months ended July 2, 2022, demonstrating strong cash flow generation.
- 6Thermo Fisher maintained a solid liquidity position, with $1.89 billion in cash and cash equivalents and significant available borrowing capacity under its credit facilities.